Quick Answer
C4 Therapeutics, Inc. reported Shares Outstanding of 96.91 million shares for fiscal year 2025.
C4 Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 96.91M | +37.2% |
| 2024 | 70.63M | +16.8% |
| 2023 | 60.47M | +23.5% |
| 2022 | 48.97M | +0.6% |
| 2021 | 48.69M | +13.1% |
| 2020 | 43.06M | +2918.3% |
| 2019 | 1.43M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 74.17M | +5.1% | +4.5% |
| June 30, 2025 | 71.01M | +3.2% | +0.0% |
| March 31, 2025 | 70.99M | +3.2% | +0.5% |
| December 31, 2024 | 70.63M | +16.8% | +0.1% |
| September 30, 2024 | 70.56M | +43.2% | +2.5% |
| June 30, 2024 | 68.82M | +40.3% | +0.1% |
| March 31, 2024 | 68.78M | +40.2% | +13.7% |
| December 31, 2023 | 60.47M | +23.5% | +22.8% |
- C4 Therapeutics, Inc. showed an increase of +37.2% in Shares Outstanding compared to the prior fiscal year.
- Over the 2019–2025 period, C4 Therapeutics, Inc.’s shares outstanding has grown by 6693.2% (from 1.43 million shares to 96.91 million shares).
- The most recent figure is from C4 Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: